Amgen collaborates with Arrakis targeting multiple therapeutic areas
Kelvin Murray/DigitalVision via Getty Images


Amgen (NASDAQ:AMGN) and Arrakis Therapeutics announce a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen.

Amgen will pay $75M upfront to Arrakis for five initial programs and will have the option to nominate additional programs.
For each program, Arrakis will be eligible for additional milestone payments, and royalties up to low double digits.
Arrakis could potentially receive several billion dollars in future payments if all milestones are met and future program options are exercised.
Recently, AMGN inked multi-target research collaboration with Generate Biomedicines.